Synovial cell sarcoma: diagnosis, treatment, and outcomes

Area of Science:

• Oncology
• Surgical Pathology
• Head and Neck Cancer Research

Background:

• Synovial cell sarcoma (SCS) is a rare mesenchymal tumor, typically affecting lower extremities.
• Head and neck SCS constitutes a small percentage of cases but presents unique clinical challenges.
• Existing literature suggests a better prognosis for head and neck SCS compared to extremity tumors, a notion challenged by recent findings.

Purpose of the Study:

• To evaluate the clinical behavior and prognosis of synovial cell sarcoma specifically in the head and neck region.
• To compare the institution's experience with head and neck SCS against established literature data.
• To identify potential needs for modifying current treatment protocols for this rare malignancy.

Main Methods:

• A retrospective chart review was conducted on patients diagnosed with head and neck SCS.
• Data were collected from January 1990 to December 2000 from the University of Louisville's Tumor Registry and affiliated hospitals.
• Information gathered included demographics, clinical presentation, histology, treatment, disease extent, recurrence, and survival, supplemented by a literature review.

Main Results:

• Five patients with head and neck SCS were analyzed, with a median age of 28.2 years.
• All patients received aggressive surgical excision and irradiation; chemotherapy was administered post-recurrence.
• High rates of local recurrence (80%) and distant metastases (100%) were observed, leading to a 5-year overall survival of 40%, lower than the literature average.

Conclusions:

• Synovial cell sarcoma of the head and neck predominantly affects young individuals and is associated with a poor prognosis.
• The aggressive nature of this neoplasm necessitates a re-evaluation of standard treatment approaches and their sequencing.
• Novel primary sites, including the ethmoid sinus and parotid gland, were identified, underscoring the varied presentation of this tumor.